Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387968 | 0.78 | NPSR1 (0.49) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL9975204 | 0.76 | CFTR (0.46) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL6425661 | 0.75 | CFTR (0.53) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL31267314 | 0.72 | CFTR (0.50) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL31347136 | 0.72 | CFTR (0.50) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL9787743 | 0.70 | CFTR (0.57) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL28524472 | 0.69 | CFTR (0.61) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL11249029 | 0.69 | CFTR (0.55) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL3949342 | 0.69 | CFTR (0.73) | CFTRGOPCNPSR1LMNAMAPT | |
| SCHEMBL30772290 | 0.69 | CFTR (0.73) | CFTRGOPCNPSR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080243-A2 | NOVEL PROCESS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | DHPS, VKORC1, DPYD | CFTR 4672/4885GOPC 3118/4885NPSR1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.